Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$4.08	$3.74	$1.66 ▼ $5.63	$1.82B	0.73	12.42 million shs	10.97 million shs
OVID Ovid Therapeutics	$2.30	$2.60	$0.27 ▼ $3.11	$429.27M	0.16	1.46 million shs	2.06 million shs
RXRX Recursion Pharmaceuticals	$3.15	$3.32	$2.77 ▼ $7.18	$1.67B	1.04	20.80 million shs	14.79 million shs
ZYME Zymeworks	$22.88	$25.71	$11.51 ▼ $29.75	$1.67B	1.15	696,683 shs	522,957 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	0.00%	-3.55%	+18.26%	+0.99%	+82.14%
OVID Ovid Therapeutics	0.00%	-4.17%	-12.55%	+17.95%	+720.84%
RXRX Recursion Pharmaceuticals	0.00%	-5.12%	+7.51%	-7.08%	-35.98%
ZYME Zymeworks	0.00%	-4.83%	-4.39%	-3.13%	+2,287,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$4.08	$3.74	$1.66 ▼ $5.63	$1.82B	0.73	12.42 million shs	10.97 million shs
OVID Ovid Therapeutics	$2.30	$2.60	$0.27 ▼ $3.11	$429.27M	0.16	1.46 million shs	2.06 million shs
RXRX Recursion Pharmaceuticals	$3.15	$3.32	$2.77 ▼ $7.18	$1.67B	1.04	20.80 million shs	14.79 million shs
ZYME Zymeworks	$22.88	$25.71	$11.51 ▼ $29.75	$1.67B	1.15	696,683 shs	522,957 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	0.00%	-3.55%	+18.26%	+0.99%	+82.14%
OVID Ovid Therapeutics	0.00%	-4.17%	-12.55%	+17.95%	+720.84%
RXRX Recursion Pharmaceuticals	0.00%	-5.12%	+7.51%	-7.08%	-35.98%
ZYME Zymeworks	0.00%	-4.83%	-4.39%	-3.13%	+2,287,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.30	Hold	$8.43	106.58% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.13	122.83% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.10	157.14% Upside
ZYME Zymeworks	2.82	Moderate Buy	$36.67	60.26% Upside

Current Analyst Ratings Breakdown

Latest OVID, IOVA, ZYME, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$28.00
6/3/2026	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
5/14/2026	OVID Ovid Therapeutics	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
5/14/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$5.00 ➝ $5.50
5/8/2026	ZYME Zymeworks	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$33.00 ➝ $34.00
5/7/2026	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$16.00 ➝ $14.00
5/7/2026	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
4/30/2026	RXRX Recursion Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$11.00 ➝ $10.00
4/27/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
4/21/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
4/21/2026	RXRX Recursion Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$263.50M	6.91	N/A	N/A	$1.76 per share	2.32
OVID Ovid Therapeutics	$7.25M	59.21	N/A	N/A	$1.00 per share	2.30
RXRX Recursion Pharmaceuticals	$74.68M	22.35	N/A	N/A	$2.14 per share	1.47
ZYME Zymeworks	$105.96M	15.77	N/A	N/A	$3.59 per share	6.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$390.98M	-$0.95	N/A	N/A	N/A	-123.92%	-50.17%	-38.77%	8/6/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.29	N/A	N/A	N/A	-240.11%	-22.51%	-18.67%	8/12/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.20	N/A	N/A	N/A	-842.95%	-54.33%	-40.60%	8/4/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$1.37	N/A	N/A	N/A	-126.92%	-37.97%	-25.31%	8/6/2026 (Estimated)

Latest OVID, IOVA, ZYME, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2026	Q1 2026	OVID Ovid Therapeutics	-$0.12	-$0.12	N/A	-$0.12	$0.06 million	N/A
5/7/2026	Q1 2026	IOVA Iovance Biotherapeutics	-$0.19	-$0.19	N/A	-$0.19	$77.84 million	$71.43 million
5/7/2026	Q1 2026	ZYME Zymeworks	-$0.10	-$0.59	-$0.49	-$0.59	$24.38 million	$2.41 million
5/6/2026	Q1 2026	RXRX Recursion Pharmaceuticals	-$0.30	-$0.22	+$0.08	-$0.22	$15.78 million	$6.47 million
3/31/2026	Q4 2025	ZYME Zymeworks	N/A	-$0.59	N/A	-$0.59	N/A	$2.41 million
3/18/2026	Q4 2025	OVID Ovid Therapeutics	-$0.10	$0.06	+$0.16	$0.06	$0.06 million	$0.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	3.60	3.15
OVID Ovid Therapeutics	0.06	10.17	10.17
RXRX Recursion Pharmaceuticals	0.01	5.47	5.47
ZYME Zymeworks	N/A	10.82	10.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
OVID Ovid Therapeutics	72.24%
RXRX Recursion Pharmaceuticals	89.06%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	7.80%
OVID Ovid Therapeutics	7.00%
RXRX Recursion Pharmaceuticals	6.65%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	500	446.50 million	411.68 million	Optionable
OVID Ovid Therapeutics	60	186.64 million	173.58 million	Optionable
RXRX Recursion Pharmaceuticals	400	529.91 million	494.67 million	Optionable
ZYME Zymeworks	460	73.02 million	48.55 million	N/A

OVID, IOVA, ZYME, and RXRX Headlines

Recent News About These Companies

Reviewing Petros Pharmaceuticals (NASDAQ:PTPI) & Zymeworks (NASDAQ:ZYME)

1 minute ago | americanbankingnews.com

Zymeworks Inc. Reports Promising Phase 1 Results for ZW191 in Platinum-Resistant Ovarian Cancer Patients

June 14 at 6:11 PM | quiverquant.comQ

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

June 14 at 6:05 PM | globenewswire.com

Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 12 at 4:31 AM | americanbankingnews.com

Zymeworks (ZYME) Gets a Buy from Wells Fargo

June 3, 2026 | theglobeandmail.com

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

May 22, 2026 | seekingalpha.com

Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity

May 14, 2026 | tipranks.com

Zymeworks’ Earnings Call Balances Progress And Pressure

May 14, 2026 | theglobeandmail.com

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 14, 2026 | financialpost.comF

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 14, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Insmed (INSM)

May 14, 2026 | theglobeandmail.com

Zymeworks Announces Participation in Upcoming Investor Conferences

May 13, 2026 | financialpost.comF

Zymeworks Announces Participation in Upcoming Investor Conferences

May 13, 2026 | globenewswire.com

Zymeworks Inc. 2026 Q1 - Results - Earnings Call Presentation

May 12, 2026 | seekingalpha.com

Here's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter Results

May 11, 2026 | finance.yahoo.com

A Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return Updates

May 9, 2026 | finance.yahoo.com

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

May 9, 2026 | seekingalpha.com

Zymeworks (ZYME) Q1 2026 Earnings Transcript

May 8, 2026 | finance.yahoo.com

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

May 7, 2026 | zacks.com

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OVID, IOVA, ZYME, and RXRX Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$4.08 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.07 -0.01 (-0.37%)

As of 06/12/2026 07:48 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Ovid Therapeutics NASDAQ:OVID

$2.30 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.28 -0.02 (-0.70%)

As of 06/12/2026 07:53 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.15 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.02 (+0.79%)

As of 06/12/2026 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Zymeworks NASDAQ:ZYME

$22.88 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$22.88 0.00 (-0.02%)

As of 06/12/2026 04:59 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OVID, IOVA, ZYME, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OVID, IOVA, ZYME, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OVID, IOVA, ZYME, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OVID, IOVA, ZYME, and RXRX Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Ovid Therapeutics NASDAQ:OVID

Recursion Pharmaceuticals NASDAQ:RXRX

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OVID, IOVA, ZYME, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OVID, IOVA, ZYME, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OVID, IOVA, ZYME, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OVID, IOVA, ZYME, and RXRX Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Ovid Therapeutics NASDAQ:OVID

Recursion Pharmaceuticals NASDAQ:RXRX

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools